Introduction
Ovarian cancer (OC) is the most lethal gynecological cancer, accounting for 4% of all cancer cases and 4.2% of deaths in women. It represents the sixth most frequently diagnosed cancer and seventh most common cause of death in females. Increased incidence of OC has been observed over the last 40 years in Poland [1] . Several issues of OC biology remain challenging, including the difficulty of diagnosis and treatment. More than 70% of OC cases are diagnosed in stage III and IV. Only 20% of patients with advanced OC survive more than 5 years; consequently OC is a critical cause of gynecological cancer death [1] . It is estimated that 1 out of 70 (1.4%) newborn females will develop OC. The highest prevalence of OC is in the 6th decade of life and 1% of women will die from the disease [2] .
Currently, decision making on how to treat OC is based on clinical and pathological variables such as age, stage, grade, histology, debulking status and response to chemotherapy. Molecular data on p53 status can provide new criteria for routine clinical assessment [3] . Mortality proves that the treatments require improvement since resistance to chemotherapy remains a challenge [4] .
Since the initial experimental demonstration of the presence of cancer stem-like cells (CSLC) in OC, the concept has gained importance in order to explain OC aggressiveness [5, 6] . CSLCs possess the capacity for self-renewal and reproduction of whole tumor populations, and they show increased tumor initiating potential (TIC) [6] . Although these cells constitute a few percent of the tumor mass, they play a crucial role in cancer chemo-resistance, metastasis and tumor recurrence. Methods to isolate ovarian CSLCs are based on surface marker expression, dye efflux and increased clonogenicity. CSLCs show expression of undifferentiated stem cell markers such as NANOG, OCT4, NESTIN, ABCG2, and BMI1, and are able to differentiate in ovarian marker expressing cells. In vitro tests for their identification and function include self-renewal, anchorage-independent growth and ability to reproduce histological characteristics of the tumor. CSLCs also enhance tumor survival by epithelial-to-mesenchymal transition (EMT, e.g. blockade of p53-conferred apoptosis) [6] . The ovarian CSLC phenotype is highly variable and does not allow a strict pattern definition [7, 8] . Concomitantly, some of the markers used to isolate CSLCs were shown to correlate with clinical features, indicating their possible use for diagnosis and prognosis of OC [9] .
This review presents a number of selected surface markers used in CSLC research, and their putative correspondence to the clinical characteristics of OC. Particular emphasis is placed on surface markers as potential prognostic factors and targets for future treatments.
Surface markers and identification of ovarian cancer stem-like cells CD133+ CD133 (prominin-1), a pentaspan transmembrane 120 kDa glycoprotein, was initially shown to be a marker for hematopoietic stem and progenitor cells [10] . It was also found on several types of stem cells in adults and is believed to suppress differentiation [11] . In ovarian cancer, CD133 expression was first investigated by Ferradina and co-workers [12, 13] , who showed that epitopes defined as CD133-1 and CD133-2 were more abundant in tumors than in normal ovary tissues and benign tumors. CD133+ OC cells showed higher clonogenic and proliferative potentials than CD133-cells [12] . Curley and coworkers showed that the CD133+ cells isolated from primary cancer were able to recapitulate the tumor characteristics in NOD/SCID mice [14] .
CD133 expression in OC cells is epigenetically regulated by methylation [15, 16] . CD133 is coexpressed with MUC4 on colony forming cells and side population cells [17] . Endothelin receptor-A (ETRA) -a molecule involved in cell migration, metastasis, and proliferation -plays an important role in CD133+ cells. ETRA was expressed on CD133+ cells isolated from primary OCs and OC cell lines and its inhibition decreased the percentage of CSLCs when induced by chemotherapy. Blockage of ETRA by chemotherapy decreased the ability of the cells to form spheres, which is a property of CSLCs [18] . In vitro inhibition of NIH:OVCAR5 CD133+ cells by dCD133KDEL (a CD133 inhibitor) selectively reduced the growth of NIH:OVCAR5-luc tumors in vivo [19] . Similar effects were observed in vitro for CCL5 chemokine and its receptors -CCR1, CCR3 and CCR5. They were upregulated in CD133+ CSLCs and their inhibition reduced cell aggressiveness [20] . The mechanism of action involves activation of the κB nuclear factor (NF-κB) and increased expression of metalloproteinase-9 (MMP9) [20] . Moreover, IL-17 promoted self-renewal of CD133+ CSLCs, mediated by NF-κB and p38 MAPK signaling pathways [21] .
OVCAR-3 cells displayed a set of aberrantly expressed miRNAs (miR-204, miR-206, miR-100, miR-200c, miR-223) in both CD133+ and CD133-cells [22] . Further studies showed that the level of miR-200a was decreased in CD133-1+ cells compared to CD133-1-. Overexpression of miR-200a in CD133/1+ decreased their migration and invasion. It also decreased and suppressed ZEB2 expression [23] . CD133+ spheroid forming OVCAR3 cells displayed upregulated levels of miR-205, miR-146a, miR-200a, miR200b, and miR-3 and downregulated the levels of miR-1201 and miR-1181 [24] . Expression of Sox2, Nanog, and Oct3/4 was higher in CD133+ than in CD133-cells [21] . This series of evidence points to CD133 as a stemness marker.
The CD133+ cells are also thought to maintain ovarian yolk sac tumor [25] . When NOY1 cells (yolk sac tumor cell line) were co-cultured with peritoneal mesothelial cells they displayed increased CD133 expression accompanied by increased colony formation, migration and invasion. Those effects were reduced by the CXCR4 blocker AMD3100 [26] .
Although CD133 was historically the first investigated stem cell surface marker and its study in OC provided substantial insight into OC progression, its mechanism of action remains elusive and it is not the only marker associated with stem-like features of OC cells.
CD44
CD44 is an integral membrane glycoprotein and the main receptor for hyaluronate (HA). It participates in specific cell-cell and cell-extracellular matrix interactions and its presence is often correlated with resistance to chemotherapy and tumor progression [27, 28] . The mechanism of CD44 action in OC includes interaction with hyaluronic acid (HA) leading to Nanog-Stat-3 activation [28] . Targeting of CD44 by CD44 siRNA together with paclitaxel delivery through a nanoscale based drug delivery system induced cell death and decreased the tumor without side effects [29] . A decrease in the CD44+ CSLC population was also obtained by using fusions cells (of dendritic cells and OC initiating cells), which were able to activate cytotoxic T lymphocytes [30] .
The combination of CD44 identification with other molecules makes CD44 a potential marker of CSLCs of OC.
CD44/CD117
The potential for CD44 along with CD117 to be a marker of epithelial ovarian stem-like cells was shown by the ability of CD44+/CD117+ cells to recapitulate the original tumor in vivo [8] . The TGF-β mediated induction tissue transglutaminase (TG2) increases the population of CD44+/CD117+ cells [31] . Upon repeated treatments with low doses of cisplatin, a population of SKOV3 cells displayed an increase of CD44, CD117 and ALDH1 expression along with features of EMT, sphere formation ability, increased motility and multidrug resistance. SKOV3 cells also exhibited higher mitochondrial mass and upregulation of cytochrome C. The survival-promoting mitochondrial complex of hexokinase-II and the voltage-dependent anion channel are an efficient target for treatment [32] . Similarly to CD133+, the CD44 and CD117 expression on SKOV3 stem cells decreased upon overexpression of miR-200c together with the stem-like properties [33] .
CD44/MyD88
Myeloid differentiation primary response gene 88 (MyD88) is a member of the toll-like receptor (TLR) family and contributes to the inflammatory microenvironment in OC [34] . CD44+/MyD88+ cells isolated from ascites and tumors from epithelial OC patients presented stem-like characteristics, including constitutive NF-κB activity, production of cytokines and chemokines (e.g. IL-1β, IL-6, IL-8, MCP-1 and GROα), high capacity for tumor reconstitution, resistance to chemotherapeutics, blocking of TNF-α-conferred apoptosis, capacity to form spheroids and ability to reinitiate the parental tumor in vivo [7] . They react with the isoflavone derivative NV-128 through mitochondrial reaction. Depression of mitochondrial function leads to a cytostatic effect via: (a) the AMPKα1 pathway resulting in mTOR inhibition; and (b) the mitochondrial MAP/ERK kinase/extracellular signal-regulated kinase pathway leading to membrane potential loss [35] . The CD44+/MyD88+ phenotype was shown to correlate with the TLR2-MyD88-NFkappaB pro-inflammatory pathway and an increased load of cancer stem-like cells in OC [36] .
CD44/E-cadherin/CD34
Presence of CD44, lack of E-cadherin and CD34 (phenotype CD44+/E-cadherin-/CD34-) marked OC cells (termed type I EOC cells) with the ability to recapitulate the tumor in vivo and participate in neovascularization [37] . These cells were further characterized by their low levels of miR-199 and miR-214, in contrast to the type II (CD44-) OC cells. These microRNAs are regulated on pri-miR-199a2, which is controlled by TWIST-1. This suggested that TWIST-1 is a "stemness" regulator in some ovarian cells [37] . TWIST-1 was found to be constitutively degraded in stem-like cells of OC; therefore additional signals are required to trigger differentiation [38] .
CD44/CD24/Epcam
Epithelial cell adhesion molecule, EpCAM, is overexpressed in several types of cancer cells [39] . The combination of three markers (out of 95) CD44+/CD24+/EpCAM+ allowed typing of cells displaying a shorter tumor-free period in vivo and increased migration and invasion characteristics in vitro. This population could be decreased (Table 2 ) [39] . Additionally E-cadherin--cells selectively expressed LIN28, which colocalized with the CD44+/CD24+/ Epcam+ markers in the OVCAR-5 cell line, and was highly expressed in transgenic murine models of OC [40] . 
CD44/CD24
The CD44+/CD24-population of OC cells displayed differentiation potential and drug resistance accompanied by higher invasion ability [41, 42] .
The expression of the claudin-4 gene was significantly higher in CD44+ OC stem cells than CD44-cells [43] . Regardless of chemo-resistance, CD44+ cells could be targeted and destroyed, both in vitro and in vivo, by Clostridium perfringens enterotoxin (CPE) [43] . CD44 RNA was shown to be a target of miR-199 [44] . CD44 expression was shown in vitro to be associated with ALDH1, the expression of which was associated with short OS of patients. ALDH1 is reported to be an OC stem-like cell marker in association with CD44 [45] .
CD44/CD166
The combination of high expression of CD44 and CD166 in OC cell lines indicated greater capacity for forming spheres and higher enzymatic activity of histone deacetylases, further implicating the role of epigenetic regulation in CSLC phenotype [46] .
CD117
The proto-oncogene CD117, known also as c-kit, encodes a type 3 transmembrane receptor activated by stem cell factor (SCF). The interaction between both molecules has been thought to be involved in embryogenesis and carcinogenesis. Expression of c-kit in OC was confirmed 
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Sphere reduction [21] two decades ago [47, 48] . Tumorigenic potential of CD117+ OC cells was confirmed in immunodeficient mice together with self-renewal and differentiation potential [49] .
CD24
CD24 is a mucin-type adhesion molecule, associated with metastatic potential [50] . A CD24+ OC cell subpopulation was enriched in stem-like characteristics for self-renewal, differentiation, ability to recapitulate the tumor, chemo-resistance and expression of "stemness" genes [51] . CD24+ cells developed a tumor more efficiently than CD24-cells, a feature which was found before only for CD133+ cells [52] . CD24/CD117 association defines a cancer stem-like, chemo-resistant side population in ovary cancer [53] .
Clinical and prognostic relevance of surface markers
Although CD133 was initially not linked to the clinical features or response to primary chemotherapy [12] , a large study including 400 OC specimens showed that CD133 expression was associated with high-grade serous carcinoma, late-stage disease, ascites level, and lack of response to chemotherapy (Table 1) . CD133 expression was also associated with shorter overall survival (OS) time and shorter disease-free survival (DFS) [54] . Multivariate analysis showed that CD133 is an independent predictor of shorter DFS [55] . CD133 (as opposed to CD44 and ALDH1) was the only marker of recurrent OC. The genes which were overexpressed in CD133+ recurrent cancer included members of the TGF-β superfamily, Hedgehog, Notch and Wnt. Stem features appeared mostly after chemotherapy [56] . CD133 marked all TIC isolated from patients with serous OC, and although its frequency varies among patients its level is similar in primary OC and metastasis [57] . Nestin was found to be an independent prognostic factor for resistance to cisplatin and OS [58] . A meta-analysis of CD133 expression in OC showed that CD133 level correlates with tumor stage and its overexpression is highly linked to reduced 2-year OS [59] .
Simultaneous expression of CD133 and ALDH1 identified cancer stem cells in OC. Expression of CD133 and ALDH1 is dependent on selection pressures such as starving, sphere culture and in vivo passaging [60] . Tumorigenicity of SKOV3 cells resides in the ALDH+/CD133+ population, which is 100 times more efficient than ALDH+/CD133-cells. The presence of ALDH+/CD133+ cells in primary OC specimens correlated with reduced DFS and OS [61] . High expression of ALDH1 was associated with shorter OS, CD44 expression, chemo-resistance, and poor clinical outcome, but this was not sufficient to define OC stem cells [45] . CD133 expression alone was characteristic for FIGO (International Federation of Gynecology and Obstetrics) stage III/IV patients and correlated with worse progression-free interval (PFI) and worse OS. Its coexpression with ALDH1 was an independent factor of PFI and OS [62] . Interestingly, oxidative stress induced by silver nanoparticles (AgNPs) was shown to be pro-apoptotic for ALDH1+/CD133+ cells, with Bcl-2 playing an important role in mitochondrial outer membrane permeabilization and loss of mitochondrial membrane potential [63] .
CD44 expression was associated with high-grade carcinoma and advanced FIGO stage, but not with OS or DFS. Moreover, expression levels of CD44 in the primary and recurrent ovarian carcinomas did not differ significantly [64] . CD44 isoforms studied on 254 tumor samples from The Cancer Genome Atlas RNAseqV2 showed a trend for longer survival in patients with high expression of the CD44v8-10 isoform. CD44v8-10 presence on the surface of primary tumor cells correlated with epithelial phenotype and better prognosis, whereas its soluble extracellular domain in ascitic fluid indicated worse prognosis [65] . OC CD44+/CD24-OC phenotype correlated with increased recurrence and shorter progression-free survival (PFS) [42] . High frequency of CD44+ or CD44+/CD19+ cells was associated with chemo-resistance, whereas the combination of both markers indicated short disease-free interval (DFI) [9] .
CD117 was present in 10 out of 25 OC, together with resistance to standard chemotherapeutics (p = 0.007) [49] . A meta-analysis of selected CD117 studies showed the relation between CD117 status and several clinical parameters including: age, FIGO stage, tumor grade, histological type. High CD117 expression meant worse OS but no correlation with DFS was found [66] .
Presence of CD24 expression was an independent predictor of survival and correlated with FIGO stage, peritoneal and lymph node metastases [67] .
Results are hardly comparable due to the differences in the approaches and scoring methods, pointing to the need for large scale studies to conclude on the right combination of markers, the reliability of expression and pattern of relative levels of interactions.
Conclusions
Despite significant progress in experimental research so far it is still difficult to, it is still difficult to describe the surface phenotype of OC stem-like cells. The use of surface markers to identify CSLCs is helpful for better understanding of the resistance mechanisms in this gynecological malignancy, and in targeting CSLCs. As data remain fragmentary, the search for precise markers is ongoing. Well-defined recommendations for clinical application of surface markers on CSLC of OC still cannot be established. The four most probable stem-like cell markers of OC are CD133, CD44, CD24 and CD117 combined with the assessment of ALDH1 activity. Such an approach could enable us to distinguish different subpopulations of OC CSLCs, and define more precise molecular linking connecting the presence of surface markers to the stem-like phenotype of cancer cells. 
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